The state of Washington currently has 19 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Seattle, Spokane, Tacoma and Vancouver.
PAH Exercise Study
NCT06941441
Recruiting
Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Washington, Seattle, Washington
Conditions: Pulmonary Arterial Hypertension (PAH), Exercise Therapy
Register for Updates
Repurposing Valsartan May Protect Against Pulmonary Hypertension
NCT06053580
Recruiting
This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/24/2025
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder
Register for Updates
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Register for Updates
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
NCT02249923
Recruiting
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
03/10/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Register for Updates
Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)
NCT03484364
Recruiting
Our Specific Aims are: 1. At the individual level, to compare within-person change in BP and secondary outcomes between the intervention and control groups. 2. At the family level, to evaluate ENACTS' effects on BP and secondary outcomes as within-person change in family members who provide primary support, and as mean change in other adult family members who are not directly engaged in the intervention. 3. At the policy level, to evaluate the intervention's ability to influence grocery store p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: National Recruitment via Facebook and Internet, Seattle, Washington
Conditions: Hypertension
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
10/09/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Pediatric Pulmonary Hypertension
Register for Updates
Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension
NCT05277870
Recruiting
The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2022
Locations: University of Washington, Seattle, Washington
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates